Actively Recruiting
Effects of Variation of Sodium Dialysate in ICU
Led by University Hospital, Montpellier · Updated on 2025-09-30
158
Participants Needed
1
Research Sites
452 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intermittent hemodialysis/diafiltration is a current renal replacement therapy (RRT) institued for ICU patients with AKI. For a better clinical tolerance, iinternational guidelines advise to use cold dialysate, increase duration session, decrease blood and dialysate flows, and increase level of sodium dialysate concentration (≥ 145mmol/l). Indeed, the use of a Na concentration dialysate \> 145 mmol/l improves intradialytic hemodynamic tolerance but it may also induce fluid overload by the transfert of sodium from the dialysate compartment to the blood. Yet, fluid overload has been strongly associated with mortality in critically ills. The investigators hypothesized that the use of a level in sodium dialysate at 140 mmol/l with slow low efficiency daily dialysis-filtration (SLEDD-f) will permit a fair intradialytic hemodynamic tolerance without the adverse effect of intradiaclytic Na loading from the dialysate. Two randomized groups of ICU AKI patients treated by SLEDD-f will be compared in terms of intradialytic hemodynamic tolerance and overload accordong to 140 or 145 mmol/l of Na in the dialysate
CONDITIONS
Official Title
Effects of Variation of Sodium Dialysate in ICU
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years old
- Acute kidney injury requiring renal replacement therapy
- Dialysis type: on line sustained low efficiency dialy dialysis-filtration
- SOFA score > 5
- Sodium serum level between 135 and 145 mmol/l
You will not qualify if you...
- Chronic kidney disease stage IV or V
- Obstructive acute kidney injury
- Renal transplantation in the year before ICU admission
- Moribund with risk of death in the next 48 hours
- Vulnerable or protected persons
- Pregnant or breastfeeding mother
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Uhmontpellier
Montpellier, Montpellier, France, 34295
Actively Recruiting
Research Team
V
vincent BRUNOT, MD
CONTACT
K
kada KLOUCHE, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here